rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Damora Therapeutics, Inc. -

DMRA · Nasdaq

Health CareBiotechnologyNot moving yet

DMRA stood above a rising 150-day average in 41 of the last 52 weekly readings, and has been out of that trend for the last 7 weeks. It is 15.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 7
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$506K
Insider sales, 12 months
$61K
Officials’ trades on record
0
Institutions holding
101 (+39)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$486KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months4
Buyers · sellers1 · 3
WhoDidSharesTraded
Jennifer JarrettDirector, President and CEObought12,500at $20.2325 Sep 2026filed 28 Sep 2026
Garrett WinslowGeneral Counselsold245at $29.986 Jul 2026filed 7 Jul 2026
Lori FirmaniChief Financial Officersold135at $21.412 Jan 2026filed 6 Jan 2026
Garrett WinslowGeneral Counselsold255at $21.382 Jan 2026filed 6 Jan 2026
Hans T. SchambyeChief Executive Officersold700at $21.382 Jan 2026filed 6 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders101+39 on the quarter
New · exited50 · 12
Reported value$1.7B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 20269,232,979$240.1M+187,498+2.1%
Fairmount Funds Management LLCunchanged · filed 14 Aug 20268,713,000$226.6M00.0%
Avoro Capital Advisors LLCunchanged · filed 14 Aug 20263,783,000$98.4M00.0%
Venrock Adviser, LLCunchanged · filed 14 Aug 20263,603,595$93.7M00.0%
BlackRock, Inc.added · filed 7 Aug 20263,162,068$82.2M+2,939,631+1321.6%
FCPM III SERVICES B.V.unchanged · filed 14 Aug 20262,441,000$63.5M00.0%
RA CAPITAL MANAGEMENT, L.P.added · filed 14 Aug 20262,399,702$62.4M+3920.0%
VIKING GLOBAL INVESTORS LPunchanged · filed 14 Aug 20262,311,082$60.1M00.0%
Jupiter Topco LLCnew · filed 14 Aug 20262,282,804$59.3M+2,282,804
JPMORGAN CHASE & COnew · filed 12 Aug 20262,058,933$49.8M+2,058,933
30 Sep 2024 – 30 Jun 2026
115598Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Jennifer Jarrett Company insiderDirector, President and CEO · last 25 Sep 20261 · 0
Andrew Cheng Company insiderDirector · last 12 Aug 20260 · 0
Garrett Winslow Company insiderGeneral Counsel · last 6 Jul 20262 · 4
Cameron Turtle Company insiderDirector · last 23 Mar 20260 · 0
Christopher W. Cain Company insiderDirector · last 23 Mar 20260 · 0
Fairmount Funds Management LLC Company insiderDirector, 10% owner · last 23 Mar 20260 · 0
Fairmount Healthcare Fund Ii L.p. Company insiderDirector, 10% owner · last 23 Mar 20260 · 0
Julianne Bruno Company insiderDirector · last 23 Mar 20260 · 0
Michael Landsittel Company insiderDirector · last 23 Mar 20260 · 0
L. Becker Hewes Company insiderChief Medical Officer · last 5 Jan 20260 · 0
Sherwin Sattarzadeh Company insiderChief Operating Officer · last 5 Jan 20260 · 0
Hans T. Schambye Company insiderChief Executive Officer · last 2 Jan 20263 · 3

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-87.7%
Interest coverFY 2024 · to 31 Dec 2024-26.37×
Share count trendFY 2024 · to 14 Mar 20250.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$257.6M

Analyst forecasts

No analyst forecasts yet.